Cellares Raises $327M Series D, Expands European Manufacturing Footprint
Event summary
- Cellares closes $327M Series D with $50M from Prime Radiant Partners.
- Prime Radiant's investment supports Cellares' European manufacturing expansion.
- Cellares' Leiden, Netherlands facility to be GMP-ready by 2027.
- Company's manufacturing platform now supports CAR T, TCR-T, and progenitor T cell therapies.
- Bristol Myers Squibb and Cabaletta Bio among key customers with active agreements.
The big picture
Cellares' Series D funding underscores the growing demand for scalable, automated cell therapy manufacturing. The investment from Prime Radiant Partners, with its deep European pharma services experience, positions Cellares to capitalize on the expanding cell therapy market. The company's strategic focus on global manufacturing infrastructure aligns with the industry's shift from scientific promise to commercial reality.
What we're watching
- Execution Risk
- The pace at which Cellares can scale its global manufacturing network while maintaining quality and regulatory compliance.
- Market Penetration
- How Cellares will leverage its Series D funding to capture market share in Europe and other key regions.
- Strategic Partnerships
- Whether Cellares can sustain its momentum with existing partners like Bristol Myers Squibb and Cabaletta Bio.
Related topics